Latest / Decera Clinical Education Oncology Podcast
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:
Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection
The recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)
Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEON
Presenters:
Rachel…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.